Log in to search using one of your social media accounts:

 

Methylphenidate Hydrochloride (QUILLICHEW ER) Extended-Release Chewable Tablets (Updated - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - February 14, 2018 Category: Drugs & Pharmacology Source Type: news

Amneal Launches Methylphenidate Hydrochloride Extended-Release Tablets, USP (CII) AB-Rated Generic for Concerta(R)
BRIDGEWATER, N.J., Feb. 5, 2018 -- (Healthcare Sales & Marketing Network) -- Amneal Pharmaceuticals has launched methylphenidate hydrochloride extended-release tablets, USP (CII) in 18, 27, 36, and 54 mg strengths. Amneal's methylphenidate is an AB-rat... Biopharmaceuticals, Generics, Product Launch Amneal Pharmaceuticals, methylphenidate, Concerta (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 5, 2018 Category: Pharmaceuticals Source Type: news

Cotempla XR ODT (Methylphenidate Extended-Release Orally Disintegrating Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 31, 2018 Category: Drugs & Pharmacology Source Type: news

Methylphenidate Hydrochloride (QUILLICHEW ER) Extended-Release Chewable Tablets (New - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - January 22, 2018 Category: Drugs & Pharmacology Source Type: news

Methylphenidate Hydrochloride (QUILLIVANT XR) for Extended-Release Oral Suspension (New - Currently in Shortage
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - January 22, 2018 Category: Drugs & Pharmacology Source Type: news

Young Women Are Using A.D.H.D. Drugs in Greater Numbers, C.D.C. Reports
Since 2003, the percentage of women filling prescriptions for drugs like Ritalin has increased nearly fivefold in some age groups. (Source: NYT Health)
Source: NYT Health - January 18, 2018 Category: Consumer Health News Authors: BENEDICT CAREY Tags: Attention Deficit Hyperactivity Disorder Women and Girls Drugs (Pharmaceuticals) Pregnancy and Childbirth Centers for Disease Control and Prevention Source Type: news

ADHD drug tied to heart defects in babies
(Reuters Health) - - Pregnant women who take drugs like Ritalin and Concerta for attention deficit hyperactivity disorder (ADHD) are more likely than those who don ’t to have babies with heart deformities and other birth defects, a recent study suggests. (Source: Reuters: Health)
Source: Reuters: Health - January 5, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Ritalin During Pregnancy May Raise Risk of Heart Defect in Baby
A new study found a small increased risk of having a baby with a heart defect if Ritalin/Concerta  (methylphenidate) was taken by the mother-to-be. (Source: WebMD Health)
Source: WebMD Health - December 13, 2017 Category: Consumer Health News Source Type: news

Ritalin During Pregnancy May Raise Risk of Heart Defect in Baby
Source: HealthDay Related MedlinePlus Pages: Attention Deficit Hyperactivity Disorder, Congenital Heart Defects, Pregnancy and Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - December 13, 2017 Category: Consumer Health News Source Type: news

ADHD drug use in pregnancy increases risk of heart defects, study finds
The attention-deficit hyperactivity disorder drug methylphenidate is associated with an increased risk of heart defects in infants whose mothers take the medication during pregnancy, according to a study published Wednesday in the journal JAMA Psychiatry. (Source: CNN.com - Health)
Source: CNN.com - Health - December 13, 2017 Category: Consumer Health News Source Type: news

ADHD medication could cause birth defects
Children exposed to ADHD drugs like Ritalin in the first trimester are more likely to have heart deformities, according to a new study by the Brigham and Women's Hospital. (Source: the Mail online | Health)
Source: the Mail online | Health - December 13, 2017 Category: Consumer Health News Source Type: news

ADHD Meds During Pregnancy Appear To Have Low Risk Of Birth Defects
Most ADHD medications appear to have no increased risk for birth defects except a very small increased risk for heart defects with methylphenidate use in the first trimester. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 13, 2017 Category: Pharmaceuticals Authors: Tara Haelle, Contributor Source Type: news

Ritalin During Pregnancy May Raise Risk of Heart Defect in Baby
WEDNESDAY, Dec. 13, 2017 -- If you take Ritalin or Concerta for attention-deficit/hyperactivity disorder (ADHD) and you plan to become pregnant, you might want to talk to your doctor about switching your medication first. A new study found a small... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 13, 2017 Category: General Medicine Source Type: news

Extended-Release Methylphenidate Oral Tablets Extended-Release Methylphenidate Oral Tablets
A newly approved extended-release formulation of methylphenidate may be another option for the management of ADHD in children.Pediatric Pharmacotherapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 5, 2017 Category: Consumer Health News Tags: Pediatrics Journal Article Source Type: news

Suicide risk reduction in youths with attention-deficit/hyperactivity disorder prescribed methylphenidate: a Taiwan nationwide population-based cohort study - Liang SH, Yang YH, Kuo TY, Liao YT, Lin TC, Lee Y, McIntyre RS, Kelsen BA, Wang TN, Chen VC.
BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) youths have increased suicide risk. Nevertheless, the beneficial effects of methylphenidate (MPH) on suicide attempt have received relatively little attention. AIMS: To investigate the MPH usage a... (Source: SafetyLit)
Source: SafetyLit - November 13, 2017 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

‘Relative’ school age biases ADHD diagnosis
Study suggests over-diagnosis in youngest Related items fromOnMedica Doctors should exercise caution in prescribing Ritalin for ADHD Attention deficit hyperactivity disorder (ADHD) New treatment options for ADHD Unhealthy diet during pregnancy may be linked to ADHD UK drug treatment of ADHD in children may have peaked (Source: OnMedica Latest News)
Source: OnMedica Latest News - October 10, 2017 Category: UK Health Source Type: news

Stimulant Cuts Apathy, Improves Cognition in Mild Alzheimer's Stimulant Cuts Apathy, Improves Cognition in Mild Alzheimer's
Improved cognition among older veterans with mild Alzheimer's disease taking methylphenidate was somewhat unexpected.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 3, 2017 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Jimmy Kimmel Thinks ‘Donald Trump Has More Flip-Flops Than a Jimmy Buffett Concert’ So He Made a Supercut
Following the death of the Graham-Cassidy bill — the latest Senate attempt to repeal Obamacare — Jimmy Kimmel took to the Live! stage to express his relief that the proposal wouldn’t pass. Senate Majority Leader Mitch McConnell announced Tuesday that the Senate would not vote on Graham-Cassidy in the wake of Senators Susan Collins and John McCain declaring their opposition to it. However, the latter’s decision drew some blowback from President Donald Trump, who tweeted in criticism of McCain reversing his position on Obamacare — a stance that Kimmel found hypocritical. “The President had...
Source: TIME.com: Top Science and Health Stories - September 27, 2017 Category: Consumer Health News Authors: Megan McCluskey Tags: Uncategorized Donald Trump Health Care Jimmy Kimmel jimmy kimmel live Late Night Television politics TV Source Type: news

Most alternative therapies for treating autism show, at best, inconclusive benefits
Dr. Shafali Jeste knows well the desperation of a parent seeking a cure for their child with autism spectrum disorder. As a clinician who both researches the causes of the disorder and treats children with autism, Jeste, UCLA associate professor of psychiatry, neurology and pediatrics and a lead investigator in the UCLA Center for Autism Research and Treatment, understands why many parents will try anything that sounds reasonable. A change to a gluten- and casein-free diet to reduce symptoms. Mega-vitamins for the same. Medical marijuana to calm. Melatonin to sleep. Omega-3 fatty acids for hyperactivity. Delaying or refusi...
Source: UCLA Newsroom: Health Sciences - September 26, 2017 Category: Universities & Medical Training Source Type: news

New delayed-release stimulant improves morning ADHD symptoms and all-day functioning
(Mary Ann Liebert, Inc./Genetic Engineering News) A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 25, 2017 Category: International Medicine & Public Health Source Type: news

A naturalistic comparison of methylphenidate and risperidone monotherapy in drug-naive youth with attention-deficit/hyperactivity disorder comorbid with oppositional defiant disorder and aggression - Masi G, Manfredi A, Nieri G, Muratori P, Pfanner C, Milone A.
BACKGROUND/PURPOSE: Attention-deficit/hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD) are frequently co-occurring in youth, but data about the pharmacological management of this comorbidity are scarce, especially when impulsive aggres... (Source: SafetyLit)
Source: SafetyLit - August 25, 2017 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

methylphenidate hydrochloride (Quillivant XR)
Title: methylphenidate hydrochloride (Quillivant XR)Category: MedicationsCreated: 7/24/2014 12:00:00 AMLast Editorial Review: 8/8/2017 12:00:00 AM (Source: MedicineNet Kids Health General)
Source: MedicineNet Kids Health General - August 8, 2017 Category: Pediatrics Source Type: news

Adderall vs. Ritalin (Differences and Similarities)
Title: Adderall vs. Ritalin (Differences and Similarities)Category: MedicationsCreated: 8/7/2017 12:00:00 AMLast Editorial Review: 8/7/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - August 7, 2017 Category: Drugs & Pharmacology Source Type: news

Association of risk of suicide attempts with methylphenidate treatment - Man KKC, Coghill D, Chan EW, Lau WCY, Hollis C, Liddle E, Banaschewski T, McCarthy S, Neubert A, Sayal K, Ip P, Schuemie MJ, Sturkenboom MCJM, Sonuga-Barke E, Buitelaar J, Carucci S, Zuddas A, Kovshoff H, Garas P, Nagy P, Inglis SK, Konrad K, H äge A, Rosenthal E, Wong ICK.
IMPORTANCE: Patients with attention-deficit/hyperactivity disorder (ADHD) are at an increased risk of attempting suicide. Stimulants, such as methylphenidate hydrochloride, are the most common treatment for ADHD, but the association between their therapeut... (Source: SafetyLit)
Source: SafetyLit - July 29, 2017 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Methylphenidate-Suicide Link Doesn't Appear Causal (FREE)
By Amy Orciari Herman Edited by Susan Sadoughi, MD Any link between the ADHD drug methylphenidate and suicide attempts does not appear to be causal, according to an observational study in JAMA Psychiatry.Using a … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - July 27, 2017 Category: Primary Care Source Type: news

Treating ADHD May Help Curb Addiction Problems
For people with the disorder, meds like Ritalin linked to lower rates of alcohol, drug abuse, study finds (Source: WebMD Health)
Source: WebMD Health - July 24, 2017 Category: Consumer Health News Source Type: news

Cotempla XR ODT (Methylphenidate Extended-Release Orally Disintegrating Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 29, 2017 Category: Drugs & Pharmacology Source Type: news

Methylphenidate disintegration from oral formulations for intravenous use by experienced substance users - Bjarnadottir GD, Johannsson M, Magnusson A, Rafnar BO, Sigurdsson E, Steingrimsson S, Asgrimsson V, Snorradottir I, Bragadottir H, Haraldsson HM.
BACKGROUND AND AIMS: Methylphenidate (MPH) is a prescription stimulant used to treat attention-deficit hyperactivity disorder. MPH is currently the preferred substance among most intravenous (i.v.) substance users in Iceland. Four types of MPH preparations... (Source: SafetyLit)
Source: SafetyLit - June 28, 2017 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Another extended-release ADHD drug wins FDA nod
Days after Neos Therapeutics (NSDQ:NEOS) nabbed U.S. regulatory approval for its controlled-release formulation of methylphenidate, Shire (NSDQ:SHPG) said it won a nod from the FDA for its long-acting ADHD drug. The drug, Mydayis, is made up of the same active ingredient in Shire’s ADHD treatment Adderall XR – amphetamine – but it is designed to last up to 16 hours. Adderall XR is formulated to control symptoms in patients for up to 12 hours. Get the full story at our sister site, Drug Delivery Business News. The post Another extended-release ADHD drug wins FDA nod appeared first on MassDev...
Source: Mass Device - June 21, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Neurological Pharmaceuticals Regulatory/Compliance Wall Street Beat neostherapeutics Shire Plc. Source Type: news

Controlled-release ADHD drug wins FDA approval
Neos Therapeutics (NSDQ:NEOS) won FDA approval yesterday for its controlled-release formulation of an old ADHD drug, methylphenidate. The company touts its product, Cotempla XR-ODT, as the 1st methylphenidate tablet designed to release medication over time instead of all at once. Get the full story at our sister site, Drug Delivery Business News. The post Controlled-release ADHD drug wins FDA approval appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 20, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Neurological Pharmaceuticals Regulatory/Compliance Wall Street Beat neostherapeutics Source Type: news

FDA Clears New Methylphenidate Formulation for ADHD FDA Clears New Methylphenidate Formulation for ADHD
Cotempla XR-ODT is a once-daily extended-release orally disintegrating tablet formulation of methylphenidate for patients aged 6 to 17 years with ADHD.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 20, 2017 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

Neos Therapeutics Announces FDA Approval of Cotempla XR-ODT (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old
DALLAS and FORT WORTH, Texas, June 19, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 19, 2017 Category: Drugs & Pharmacology Source Type: news

The effects of methylphenidate on the neural signatures of sustained attention - Dockree PM, Barnes JJ, Matthews N, Dean AJ, Abe R, Nandam LS, Kelly SP, Bellgrove MA, O'Connell RG.
We examined how MPH influenced known electrophysiological precursors of lapsing attenti... (Source: SafetyLit)
Source: SafetyLit - June 14, 2017 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Ritalin LA (Methylphenidate Hydrochloride Extended-Release Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 9, 2017 Category: Drugs & Pharmacology Source Type: news

How Do I Keep My Prescription Stimulant Safe At College?
Discussion Going away to college presents new and exciting opportunities for young adults. It also is an important time for transitioning many adult responsibilities to the young adult too. Keeping safe is important and safety tips for college can be reviewed here. Any medication can be abused. Prescription stimulants are no different. Normally prescription stimulants are used for treatment of attention deficit disorder, narcolepsy and treatment resistant depression. They can help increase alertness, attention, and energy, cognition, learning and memory. However for these reasons and because they are easy to obtain and r...
Source: PediatricEducation.org - June 5, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Ritalin found to cause serious brain chemistry changes and an increase in risk-taking behaviors
(Natural News) An animal study recently published in the Journal of Neural Transmission revealed that nonprescription use of the stimulant drug Ritalin, a common treatment for attention deficit hyperactivity disorder (ADHD), was associated with increased risk-taking behaviors, sleep disruption, and other unpleasant side effects. As part of the study, a team of researchers at the University at Buffalo Research Institute on... (Source: NaturalNews.com)
Source: NaturalNews.com - May 30, 2017 Category: Consumer Health News Source Type: news

Methylphenidate Hydrochloride Tablets, USP (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - May 17, 2017 Category: Drugs & Pharmacology Source Type: news

Nonprescription use of Ritalin linked to adverse side effects, study finds
New research has explored the potential side effects of the stimulant drug Ritalin on those without ADHD showed changes in brain chemistry associated with risk-taking behavior, sleep disruption and other undesirable effects. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 15, 2017 Category: Science Source Type: news

Nonprescription use of Ritalin linked to adverse side effects, UB study finds
(University at Buffalo) New research from the University at Buffalo Research Institute on Addictions that explored the potential side effects of the stimulant drug Ritalin on those without ADHD showed changes in brain chemistry associated with risk-taking behavior, sleep disruption and other undesirable effects. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 15, 2017 Category: International Medicine & Public Health Source Type: news

Simulated driving skills evaluation of teenagers with attention deficit hyperactivity disorder before driving lessons - Ratzon NZ, Lunievsky EK, Ashkenasi A, Laks J, Cohen HA.
OBJECTIVE: We evaluated the driving skills of teenagers with attention deficit hyperactivity disorder (ADHD) during simulated driving before starting driving lessons and observed whether methylphenidate (MPH) affected their performance. METHOD: Six... (Source: SafetyLit)
Source: SafetyLit - April 26, 2017 Category: Global & Universal Tags: Age: Adolescents Source Type: news

Suicide attempt with high dose long acting methylphenidate ingestion: a case presentation - Erkuran HO, Cakaloz APB, Onen O, Kutlu A.
Attention Deficit and Hyperactivity Disorder (ADHD) is among the most commonly encountered neurodevelopmental disorders in childhood with its reported worldwide prevalance as 5%. Among the recommended treatment regimens as stimulants, the most frequently a... (Source: SafetyLit)
Source: SafetyLit - April 19, 2017 Category: Global & Universal Tags: Alcohol and Other Drugs Source Type: news

Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review
In conclusion, while available evidence addressed mainly the efficacy and tolerability of psychostimulants and non-psychostimulants for ADHD core symptoms in the short term, we still need further empirical support for the non-pharmacological and multimodal treatments. A comprehensive evidence-informed hierarchy of ADHD drugs based on their efficacy and tolerability is not yet available but it should be the next research priority in the field. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 16, 2017 Category: Consumer Health News Source Type: news

Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater.
A recent Cochrane review assessed the efficacy of methylphenidate for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. Notwithstanding the moderate-to-large effect sizes for ADHD symptom reduction found in the meta-analysis, the authors concluded that the quality of the evidence is low and therefore the true magnitude of these effects remains uncertain. We identified a number of major concerns with the review, in the domains of study inclusion, approaches to quality assessment and interpretation of data relating to serious adverse events as well as of the clinical implications of the reported ef...
Source: Current Awareness Service for Health (CASH) - March 16, 2017 Category: Consumer Health News Source Type: news

Evidence on methylphenidate in children and adolescents with ADHD is in fact of very low quality
Banaschewski and colleagues from the European Attention Deficit Hyperactivity Disorder (ADHD) guideline group make a number of critical comments regarding our systematic review on methylphenidate for children and adolescents with ADHD. In this article, we present our views, showing that our trial selection was not flawed and was undertaken with scientific justification. Similarly, our data collection and interpretation was systematic and correct. We have followed a sound methodology for assessing risk of bias and our conclusions are not misleading. We acknowledge that different researchers might make risk of bias judgments...
Source: Current Awareness Service for Health (CASH) - March 16, 2017 Category: Consumer Health News Source Type: news

Cognitive enhancing drugs can improve chess play, scientists show
The first study to both show and measure the effects of cognitive-enhancing drugs such as modafinil, methylphenidate (best known under the trade name Ritalin), and caffeine, on chess play is being published. Research shows significant cognitive improvements for modafinil and methylphenidate, and may influence how these drugs are used off-label in a range of activities. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 6, 2017 Category: Science Source Type: news

Scientists show cognitive-enhancing drugs can improve chess play
(European College of Neuropsychopharmacology) The first study to both show and measure the effects of cognitive-enhancing drugs such as modafinil, methylphenidate (best known under the trade name Ritalin), and caffeine, on chess play is being published in the March edition of the peer-reviewed journal European Neuropsychopharmacology. This shows significant cognitive improvements for modafinil and methylphenidate, and may have influence how these drugs are used off-label in a range of activities. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 6, 2017 Category: Global & Universal Source Type: news

The influence of stimulants on performance when playing chess
(Johannes Gutenberg Universitaet Mainz) High-performance tournament chess players can actually enhance the highly complex cognitive functions they require by taking substances such as the CNS stimulant methylphenidate or the wakefulness promoter modafinil and thus win more chess matches -- unless they are under time pressure. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 6, 2017 Category: Global & Universal Source Type: news

FDA gives Lannett more time to make its case for ADHD drug
The Food and Drug Administration has decided to give Lannett Co. Inc. more time to show why its generic ADHD drug should be allowed to remain in the market. Back in October, the FDA informed the Northeast Philadelphia generic drug manufacturer that the agency was preparing to withdraw its approval of the company’s Methylphenidate Hydrochloride extended-release tablets, prescribed to treat attention deficit hyperactivity disorder, based in part on re ports by patients that the therapeutics benefits… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 22, 2017 Category: Pharmaceuticals Authors: John George Source Type: news

Drugs Vanish at Some VA Hospitals
WASHINGTON (AP) — Federal authorities are stepping up investigations at Department of Veterans Affairs medical centers due to a sharp increase in opioid theft, missing prescriptions or unauthorized drug use by VA employees since 2009, according to government data obtained by The Associated Press. Doctors, nurses or pharmacy staff at federal hospitals — the vast majority within the VA system — siphoned away controlled substances for their own use or street sales, or drugs intended for patients simply disappeared. Aggravating the problem is that some VA hospitals have been lax in tracking drug supplies. Co...
Source: Arkansas Business - Health Care - February 20, 2017 Category: American Health Source Type: news

Methylin Oral Solution (Methylphenidate HCl Oral Solution 5 mg/5 mL and 10 mg/5 mL) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 23, 2017 Category: Drugs & Pharmacology Source Type: news